Immunocore Holdings delivered a sharp reversal of its recent slide on Wednesday, rallying more than 10% after Q1 results beat expectations on profitability while revealing a pipeline full of upcoming readouts.
The earnings beat was the headline: EPS came in at $0.25 against an estimate of -$0.25, a $0.51 beat. Revenue of $106.7M missed the $107.7M consensus by a thin margin, but the profitability swing dominated the reaction. The stock had lost roughly 17% year-to-date heading into the print, closing at $30.73 on May 6 before the results landed — making the rally a meaningful recovery off a depressed base. That kind of setup, where a beaten-down stock meets a positive surprise, is consistent with the sharp move seen. The prior print in February saw a -4.9% day-one reaction, suggesting the market has been quick to punish here; the reverse is now true.
The pipeline update added fuel. Management flagged plans to file a CTA or IND for IMC-U120AI in H2 2026. Phase 1/2 data from brenetafusp and IMC-P115C trials are also expected in H2, with initial data from IMC-R117C targeting colorectal and GI cancers pencilled for 2027. These catalysts give the bull case concrete near-term anchors. ORTEX factor scores back the earnings story — the company ranks in the 93rd percentile for EPS surprise and the 85th percentile for 90-day EPS momentum, suggesting consistent upward pressure on estimates heading into the print.
The options market had already shifted firmly toward calls before results. The put/call ratio was running at just 0.41 on May 6, near its 52-week low of 0.32 and well below its 20-day mean of 2.30. That extreme skew — driven partly by the sharp collapse in put activity during April after the PCR had been running above 6.0 for most of March and early April — pointed to growing conviction among options traders that the downside scenario was less likely. Short positioning tells a similar story: short interest has been trending down from above 10.4M shares in early April to roughly 9.8M, with borrow costs at a modest 0.67% and borrow availability still loose. There is no meaningful squeeze pressure in the lending market heading into the recovery.
The analyst debate centres on KIMMTRAK's competitive durability. Bulls — and Jefferies' March downgrade to Hold with a $33 target now looks squarely challenged by the stock's post-earnings move back toward those levels — point to expanding label opportunities and a $5B risk-adjusted valuation case from firms like HC Wainwright, which holds a $100 target. Bears focus on IDEAYA's competing HLA-A*02:01-negative program for uveal melanoma, which could address the full mUM population with more scheduling flexibility, and on the company's ongoing cash requirements. With the analyst consensus mean target at $63.78 and Needham recently raising to $75, the Q1 beat is now testing whether the Street upgrades its view of KIMMTRAK's commercial trajectory — or treats the profitability swing as a one-quarter event.
See the live data behind this article on ORTEX.
Open IMCR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
